RxDoctor Payments Data

John Downey, DO

Pain Medicine · Augusta, GANPI 1104884246

Payments from drug & device makers

$518in general payments, 2019–2025

Across 16 payments — averaging $32.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$133
  • Boston Scientific$129
  • Biodelivery Sciences International, Inc.$91
  • Collegium Pharmaceutical, Inc.$67
  • GRT US Holding, Inc.$45
  • Virtus Pharmaceuticals LLC$24
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$42783%
  • Education$9117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 25th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$554,491
Medicare patients
513
Services billed
11,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl190$137,253
Xtampza ErOxycodone Myristate110$99,088
Oxycodone Hcl4,235$95,903
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen3,011$91,119
Fentanyl431$54,860
NucyntaTapentadol Hcl39$51,349
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,632$40,676
BelbucaBuprenorphine Hcl40$37,407
PercocetOxycodone Hcl/Acetaminophen11$28,875
Oxymorphone Hcl ErOxymorphone Hcl12$17,166
Morphine Sulfate ErMorphine Sulfate447$14,195
Hydromorphone ErHydromorphone Hcl41$11,979
Hydromorphone Hcl585$11,875
Morphine Sulfate398$11,414
Pregabalin441$8,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Belbuca$67$187,844189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →